Circulation. 2003;107:992-995
Published online before print February 3, 2003, doi: 10.1161/01.CIR.0000050628.11305.30
Published online before print February 3, 2003, doi: 10.1161/01.CIR.0000050628.11305.30
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:992.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
The Antioxidant Acetylcysteine Reduces Cardiovascular Events in Patients With End-Stage Renal Failure
A Randomized, Controlled Trial
From Med Klinik IV, Univ.-Klinik Benjamin Franklin, Freie Universität Berlin, Germany
Correspondence to Dr Martin Tepel, Univ.-Klinik Benjamin Franklin, Freie Universität Berlin, Med. Klinik IV, Hindenburgdamm 30, D-12200 Berlin, Germany. E-mail Tepel{at}zedat.fu-berlin.de
Background— Patients with end-stage renal failure have increased oxidative stress and show elevated cardiovascular mortality. Whether increased cardiovascular events can be prevented by the administration of antioxidants is unknown.
Methods and Results— We evaluated the effects of acetylcysteine, a thiol-containing antioxidant, on cardiovascular events in patients undergoing hemodialysis. A prospective, randomized, placebo-controlled trial was conducted between October 1, 1999, and September 30, 2001, in 134 patients (76 male and 58 female) with a mean age of 62±16 years (mean±SD) who had been undergoing maintenance hemodialysis for a minimum of 3 months 3 times weekly in an ambulatory center. Median (range) follow-up was 14.5 (1 to 24) months. Patients were randomly assigned either to receive acetylcysteine (600 mg BID) or placebo. The primary end point was a composite variable consisting of cardiac events including fatal and nonfatal myocardial infarction, cardiovascular disease death, need for coronary angioplasty or coronary bypass surgery, ischemic stroke, peripheral vascular disease with amputation, or need for angioplasty. Secondary end points included each of the component outcomes, total mortality, and cardiovascular mortality. A total of 18 (28%) of the 64 hemodialysis patients assigned to acetylcysteine group and 33 (47%) of the 70 hemodialysis patients assigned to control group had a primary end point (relative risk, 0.60 [95% CI, 0.38 to 0.95], P=0.03). No significant differences in secondary end points or total mortality were detected.
Conclusions— In hemodialysis patients, treatment with acetylcysteine (600 mg BID) reduces composite cardiovascular end points.
Key Words: antioxidants • drugs • mortality
This article has been cited by other articles:
 |
|
 |
|
  M. Kimmel, M. Butscheid, S. Brenner, U. Kuhlmann, U. Klotz, and D. M. Alscher Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1241 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Stenvinkel, J. J. Carrero, J. Axelsson, B. Lindholm, O. Heimburger, and Z. Massy Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle? Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 505 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Covic, P. Gusbeth-Tatomir, and D. Goldsmith Negative outcome studies in end-stage renal disease: how dark are the storm clouds? Nephrol. Dial. Transplant., January 1, 2008; 23(1): 56 - 61. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sachse and G. Wolf Angiotensin II Induced Reactive Oxygen Species and the Kidney J. Am. Soc. Nephrol., September 1, 2007; 18(9): 2439 - 2446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Efrati, S. Berman, Y. Siman-Tov, R. Lotan, Z. Averbukh, J. Weissgarten, and A. Golik N-acetylcysteine attenuates NSAID-induced rat renal failure by restoring intrarenal prostaglandin synthesis Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1873 - 1881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.C. Edwards, R.P. Steeds, C.J. Ferro, and J.N. Townend The treatment of coronary artery disease in patients with chronic kidney disease QJM, November 1, 2006; 99(11): 723 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Svensson, E. B. Schmidt, K. A. Jorgensen, J. H. Christensen, and on behalf of the OPACH Study Group N-3 Fatty Acids as Secondary Prevention against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis: A Randomized, Placebo-Controlled Intervention Trial Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 780 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Weiss, N. Ide, T. Abahji, L. Nill, C. Keller, and U. Hoffmann Aged Garlic Extract Improves Homocysteine-Induced Endothelial Dysfunction in Macro- and Microcirculation J. Nutr., March 1, 2006; 136(3): 750S - 754S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Berl and W. Henrich Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment Clin. J. Am. Soc. Nephrol., January 1, 2006; 1(1): 8 - 18. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ikewaki, J. R. Schaefer, M. E. Frischmann, K. Okubo, T. Hosoya, S. Mochizuki, B. Dieplinger, E. Trenkwalder, H. Schweer, F. Kronenberg, et al. Delayed In Vivo Catabolism of Intermediate-Density Lipoprotein and Low-Density Lipoprotein in Hemodialysis Patients as Potential Cause of Premature Atherosclerosis Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2615 - 2622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. CY, M. CE, D. J, G. AS, I. C, T. E, C. HC, L. M, R. S, R. ER, et al. Which Comes First--Renal Dysfunction or High Blood Pressure?: Elevated Blood Pressure and Risk of End-Stage Renal Disease in Subjects without Baseline Kidney Disease. Arch Intern Med 165: 923-928, 2005 J. Am. Soc. Nephrol., October 1, 2005; 16(10): 2817 - 2820. [Full Text] [PDF]
|
|
|
|
|
|
R. Deicher, F. Ziai, C. Bieglmayer, M. Schillinger, and W. H. Horl Low Total Vitamin C Plasma Level Is a Risk Factor for Cardiovascular Morbidity and Mortality in Hemodialysis Patients J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1811 - 1818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Gleeson and S. Bulugahapitiya Contrast-Induced Nephropathy Am. J. Roentgenol., December 1, 2004; 183(6): 1673 - 1689. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Stewart, A. Kohen, D. Brouder, F. Rahim, S. Adler, R. Garrick, and M. S. Goligorsky Noninvasive interrogation of microvasculature for signs of endothelial dysfunction in patients with chronic renal failure Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2687 - H2696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gupta, Y. Birnbaum, and B. F. Uretsky The renal patient with coronary artery disease: Current concepts and dilemmas J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1343 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bourraindeloup, C. Adamy, G. Candiani, M. Cailleret, M.-C. Bourin, T. Badoual, J. B. Su, S. Adubeiro, F. Roudot-Thoraval, J.-L. Dubois-Rande, et al. N-Acetylcysteine Treatment Normalizes Serum Tumor Necrosis Factor-{alpha} Level and Hinders the Progression of Cardiac Injury in Hypertensive Rats Circulation, October 5, 2004; 110(14): 2003 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Santangelo, V. Witko-Sarsat, T. Drueke, and B. Descamps-Latscha Restoring glutathione as a therapeutic strategy in chronic kidney disease Nephrol. Dial. Transplant., August 1, 2004; 19(8): 1951 - 1955. [Full Text] [PDF]
|
|
|
|
|
|
D. Hucks, R. C. Thuraisingham, M. J. Raftery, and M. M. Yaqoob Homocysteine induced impairment of nitric oxide-dependent vasorelaxation is reversible by the superoxide dismutase mimetic TEMPOL Nephrol. Dial. Transplant., August 1, 2004; 19(8): 1999 - 2005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M W Yerkey, S J Kernis, B A Franklin, K R Sandberg, and P A McCullough Renal dysfunction and acceleration of coronary disease Heart, August 1, 2004; 90(8): 961 - 966. [Full Text] [PDF]
|
|
|
|
|
|
P. Stenvinkel, U. Diczfalusy, B. Lindholm, and O. Heimburger Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy Nephrol. Dial. Transplant., April 1, 2004; 19(4): 972 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Robinson Renal Disease, Homocysteine, and Cardiovascular Complications Circulation, January 27, 2004; 109(3): 294 - 295. [Full Text] [PDF]
|
|
|
|
|
|
A. Scholze, C. Rinder, J. Beige, R. Riezler, W. Zidek, and M. Tepel Acetylcysteine Reduces Plasma Homocysteine Concentration and Improves Pulse Pressure and Endothelial Function in Patients With End-Stage Renal Failure Circulation, January 27, 2004; 109(3): 369 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Rabelink Cardiovascular risk in patients with renal disease: treating the risk or treating the risk factor? Nephrol. Dial. Transplant., January 1, 2004; 19(1): 23 - 26. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Hypertension, November 1, 2003; 42(5): 1050 - 1065. [Full Text] [PDF]
|
|
|
|
|
|
K. K. Griendling and G. A. FitzGerald Oxidative Stress and Cardiovascular Injury: Part II: Animal and Human Studies Circulation, October 28, 2003; 108(17): 2034 - 2040. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation, October 28, 2003; 108(17): 2154 - 2169. [Full Text] [PDF]
|
|
|
|
|
|
T. B. Drueke, B. Descamps-Latscha, and F. Locatelli Stopping a medical research project for financial reasons Nephrol. Dial. Transplant., October 1, 2003; 18(10): 1982 - 1983. [Full Text] [PDF]
|
|
|
|
|
|
C. A. Herzog How to Manage the Renal Patient with Coronary Heart Disease: The Agony and the Ecstasy of Opinion-Based Medicine J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2556 - 2572. [Full Text] [PDF]
|
|
|
|
|
|
F. Locatelli, B. Canaud, K.-U. Eckardt, P. Stenvinkel, C. Wanner, and C. Zoccali Oxidative stress in end-stage renal disease: an emerging threat to patient outcome Nephrol. Dial. Transplant., July 1, 2003; 18(7): 1272 - 1280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Stenvinkel, R. Pecoits-Filho, and B. Lindholm Coronary Artery Disease in End-Stage Renal Disease: No Longer a Simple Plumbing Problem J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1927 - 1939. [Full Text] [PDF]
|
|